These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 8347481)

  • 1. Further evaluation of nicotinamide and carbogen as a strategy to reoxygenate hypoxic cells in vivo: importance of nicotinamide dose and pre-irradiation breathing time.
    Chaplin DJ; Horsman MR; Siemann DW
    Br J Cancer; 1993 Aug; 68(2):269-73. PubMed ID: 8347481
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The radiation response of KHT sarcomas following nicotinamide treatment and carbogen breathing.
    Siemann DW; Horsman MR; Chaplin DJ
    Radiother Oncol; 1994 May; 31(2):117-22. PubMed ID: 8066190
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Radiosensitization of SCCVII tumours and normal tissues by nicotinamide and carbogen: analysis by micronucleus assay.
    Ono K; Masunaga S; Akuta K; Akaboshi M; Abe M
    Radiother Oncol; 1993 Aug; 28(2):162-7. PubMed ID: 8248558
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of the enhancement of tumor responses to fractionated irradiation by SR 4233 (tirapazamine) and by nicotinamide with carbogen.
    Dorie MJ; Menke D; Brown JM
    Int J Radiat Oncol Biol Phys; 1994 Jan; 28(1):145-50. PubMed ID: 8270435
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Radiosensitizing effect of nicotinamide and carbogen combined in fractionated pions or x-rays in SCCVII tumors.
    Ohizumi Y; Lam GK; Pickles T; Fryer C; Chaplin DJ
    Radiat Med; 1995; 13(6):291-5. PubMed ID: 8850370
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nicotinamide, Fluosol DA and Carbogen: a strategy to reoxygenate acutely and chronically hypoxic cells in vivo.
    Chaplin DJ; Horsman MR; Aoki DS
    Br J Cancer; 1991 Jan; 63(1):109-13. PubMed ID: 1846549
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Radiosensitisation in normal tissues with oxygen, carbogen or nicotinamide: therapeutic gain comparisons for fractionated x-ray schedules.
    Rojas A; Vojnovic B; Johns H; Joiner MC; Martindale C; Fowler JF; Denekamp J
    Radiother Oncol; 1996 Apr; 39(1):53-64. PubMed ID: 8735494
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reducing acute and chronic hypoxia in tumours by combining nicotinamide with carbogen breathing.
    Horsman MR; Nordsmark M; Khalil AA; Hill SA; Chaplin DJ; Siemann DW; Overgaard J
    Acta Oncol; 1994; 33(4):371-6. PubMed ID: 8018368
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of combined nicotinamide and carbogen treatments in human tumour xenografts: oxygenation and tumour control studies.
    Stüben G; Stuschke M; Knühmann K; Horsman MR; Sack H
    Radiother Oncol; 1998 Aug; 48(2):143-8. PubMed ID: 9783885
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Perfusion changes in the RIF-1 tumour and normal tissues after carbogen and nicotinamide, individually and combined.
    Honess DJ; Bleehen NM
    Br J Cancer; 1995 Jun; 71(6):1175-80. PubMed ID: 7779707
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preclinical studies on how to deal with patient intolerance to nicotinamide and carbogen.
    Horsman MR; Overgaard J
    Radiother Oncol; 2004 Mar; 70(3):301-9. PubMed ID: 15064017
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Carbogen and nicotinamide: expectations too high?
    Brown JM
    Radiother Oncol; 1992 Jun; 24(2):75-6. PubMed ID: 1386679
    [No Abstract]   [Full Text] [Related]  

  • 13. Carbogen and nicotinamide: expectations too high? (response to J. Martin Brown).
    Horsman MR
    Radiother Oncol; 1992 Jun; 24(2):121-2. PubMed ID: 1386677
    [No Abstract]   [Full Text] [Related]  

  • 14. Accelerated radiotherapy with carbogen and nicotinamide (ARCON) for laryngeal cancer.
    Kaanders JH; Pop LA; Marres HA; Liefers J; van den Hoogen FJ; van Daal WA; van der Kogel AJ
    Radiother Oncol; 1998 Aug; 48(2):115-22. PubMed ID: 9783882
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Extrapolations from laboratory and preclinical studies for the use of carbogen and nicotinamide in radiotherapy.
    Rojas A; Joiner MC; Denekamp J
    Radiother Oncol; 1992 Jun; 24(2):123-4. PubMed ID: 1386678
    [No Abstract]   [Full Text] [Related]  

  • 16. Enhancement of tumor radiosensitivity and reduced hypoxia-dependent binding of a 2-nitroimidazole with normobaric oxygen and carbogen: a therapeutic comparison with skin and kidneys.
    Rojas A; Joiner MC; Hodgkiss RJ; Carl U; Kjellen E; Wilson GD
    Int J Radiat Oncol Biol Phys; 1992; 23(2):361-6. PubMed ID: 1587757
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of the effectiveness of tirapazamine and carbogen with nicotinamide in enhancing the response of a human tumor xenograft to fractionated irradiation.
    el-Said A; Menke D; Dorie MJ; Brown JM
    Radiat Oncol Investig; 1999; 7(3):163-9. PubMed ID: 10406058
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fractionated irradiation combined with carbogen breathing and nicotinamide of two human glioblastomas grafted in nude mice.
    Sun LQ; Coucke PA; Mirimanoff RO; Buchegger F
    Radiat Res; 2001 Jan; 155(1 Pt 1):26-31. PubMed ID: 11121212
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Early skin response to fractionated doses of pions for determining therapeutic gain factors.
    Ohizumi Y; Lam GK; Pickles T; Chaplin DJ
    Tokai J Exp Clin Med; 1996 Jun; 21(2):69-75. PubMed ID: 9239808
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical outcome and tumour microenvironmental effects of accelerated radiotherapy with carbogen and nicotinamide.
    Bussink J; Kaanders JH; Van der Kogel AJ
    Acta Oncol; 1999; 38(7):875-82. PubMed ID: 10606417
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.